Korean Journal of Radiology

  • 제22권3호
  • /
  • Pages.464-475
  • /
  • 2021
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

Volume and Mass Doubling Time of Lung Adenocarcinoma according to WHO Histologic Classification

  • Jung Hee Hong (Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Samina Park (Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Hyungjin Kim (Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Jin Mo Goo (Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • In Kyu Park (Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Chang Hyun Kang (Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Young Tae Kim (Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, Seoul National University Hospital) ;
  • Soon Ho Yoon (Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital)
  • 투고 : 2020.02.17
  • 심사 : 2020.06.13
  • 발행 : 2021.03.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: This study aimed to evaluate the tumor doubling time of invasive lung adenocarcinoma according to the International Association of the Study for Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) histologic classification. Materials and Methods: Among the 2905 patients with surgically resected lung adenocarcinoma, we retrospectively included 172 patients (mean age, 65.6 ± 9.0 years) who had paired thin-section non-contrast chest computed tomography (CT) scans at least 84 days apart with the same CT parameters, along with 10 patients with squamous cell carcinoma (mean age, 70.9 ± 7.4 years) for comparison. Three-dimensional semiautomatic segmentation of nodules was performed to calculate the volume doubling time (VDT), mass doubling time (MDT), and specific growth rate (SGR) of volume and mass. Multivariate linear regression, one-way analysis of variance, and receiver operating characteristic curve analyses were performed. Results: The median VDT and MDT of lung cancers were as follows: acinar, 603.2 and 639.5 days; lepidic, 1140.6 and 970.1 days; solid/micropapillary, 232.7 and 221.8 days; papillary, 599.0 and 624.3 days; invasive mucinous, 440.7 and 438.2 days; and squamous cell carcinoma, 149.1 and 146.1 days, respectively. The adjusted SGR of volume and mass of the solid-/micropapillary-predominant subtypes were significantly shorter than those of the acinar-, lepidic-, and papillary-predominant subtypes. The histologic subtype was independently associated with tumor doubling time. A VDT of 465.2 days and an MDT of 437.5 days yielded areas under the curve of 0.791 and 0.795, respectively, for distinguishing solid-/micropapillary-predominant subtypes from other subtypes of lung adenocarcinoma. Conclusion: The tumor doubling time of invasive lung adenocarcinoma differed according to the IASCL/ATS/ERS histologic classification.

키워드

참고문헌

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424  https://doi.org/10.3322/caac.21492
  2. Meza R, Meernik C, Jeon J, Cote ML. Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLoS One 2015;10:e0121323 
  3. Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 2015;4:36-54 
  4. Pinsky PF, Church TR, Izmirlian G, Kramer BS. The national lung screening trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 2013;119:3976-3983  https://doi.org/10.1002/cncr.28326
  5. Mizuno T, Masaoka A, Ichimura H, Shibata K, Tanaka H, Niwa H. Comparison of actual survivorship after treatment with survivorship predicted by actual tumor-volume doubling time from tumor diameter at first observation. Cancer 1984;53:2716-2720  https://doi.org/10.1002/1097-0142(19840615)53:12<2716::AID-CNCR2820531227>3.0.CO;2-N
  6. Arai T, Kuroishi T, Saito Y, Kurita Y, Naruke T, Kaneko M. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Jpn J Clin Oncol 1994;24:199-204 
  7. Honda O, Johkoh T, Sekiguchi J, Tomiyama N, Mihara N, Sumikawa H, et al. Doubling time of lung cancer determined using three-dimensional volumetric software: comparison of squamous cell carcinoma and adenocarcinoma. Lung Cancer 2009;66:211-217  https://doi.org/10.1016/j.lungcan.2009.01.018
  8. Mackintosh JA, Marshall HM, Yang IA, Bowman RV, Fong KM. A retrospective study of volume doubling time in surgically resected non-small cell lung cancer. Respirology 2014;19:755-762  https://doi.org/10.1111/resp.12311
  9. Obayashi K, Shimizu K, Nakazawa S, Nagashima T, Yajima T, Kosaka T, et al. The impact of histology and ground-glass opacity component on volume doubling time in primary lung cancer. J Thorac Dis 2018;10:5428-5434  https://doi.org/10.21037/jtd.2018.08.118
  10. Wilson DO, Ryan A, Fuhrman C, Schuchert M, Shapiro S, Siegfried JM, et al. Doubling times and CT screen-detected lung cancers in the Pittsburgh Lung Screening Study. Am J Respir Crit Care Med 2012;185:85-89  https://doi.org/10.1164/rccm.201107-1223OC
  11. Winer-Muram HT, Jennings SG, Tarver RD, Aisen AM, Tann M, Conces DJ, et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. Radiology 2002;223:798-805  https://doi.org/10.1148/radiol.2233011026
  12. Lee HJ, Kim YT, Kang CH, Zhao B, Tan Y, Schwartz LH, et al. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology 2013;268:254-264  https://doi.org/10.1148/radiol.13112553
  13. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011;6:244-285  https://doi.org/10.1097/JTO.0b013e318206a221
  14. Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol 2015;33:3439-3446  https://doi.org/10.1200/JCO.2014.58.8335
  15. Ujiie H, Kadota K, Chaft JE, Buitrago D, Sima CS, Lee MC, et al. Solid predominant histologic subtype in resected stage I lung adenocarcinoma is an independent predictor of early, extrathoracic, multisite recurrence and of poor postrecurrence survival. J Clin Oncol 2015;33:2877-2884  https://doi.org/10.1200/JCO.2015.60.9818
  16. Wang L, Jiang W, Zhan C, Shi Y, Zhang Y, Lin Z, et al. Lymph node metastasis in clinical stage IA peripheral lung cancer. Lung Cancer 2015;90:41-46  https://doi.org/10.1016/j.lungcan.2015.07.003
  17. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013;8:52-61  https://doi.org/10.1097/JTO.0b013e3182769aa8
  18. Devaraj A, van Ginneken B, Nair A, Baldwin D. Use of volumetry for lung nodule management: theory and practice. Radiology 2017;284:630-644  https://doi.org/10.1148/radiol.2017151022
  19. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer 1961;14:1272-1294  https://doi.org/10.1002/1097-0142(196111/12)14:6<1272::AID-CNCR2820140618>3.0.CO;2-H
  20. Jennings SG, Winer-Muram HT, Tann M, Ying J, Dowdeswell I. Distribution of stage I lung cancer growth rates determined with serial volumetric CT measurements. Radiology 2006;241:554-563  https://doi.org/10.1148/radiol.2412051185
  21. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Tazelaar HD, et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology 2007;242:555-562  https://doi.org/10.1148/radiol.2422052090
  22. Quint LE, Cheng J, Schipper M, Chang AC, Kalemkerian G. Lung lesion doubling times: values and variability based on method of volume determination. Clin Radiol 2008;63:41-48  https://doi.org/10.1016/j.crad.2007.07.011
  23. Field JK, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE, et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax 2016;71:161-170  https://doi.org/10.1136/thoraxjnl-2015-207140
  24. Pastorino U, Rossi M, Rosato V, Marchiano A, Sverzellati N, Morosi C, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012;21:308-315  https://doi.org/10.1097/CEJ.0b013e328351e1b6
  25. van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009;361:2221-2229  https://doi.org/10.1056/NEJMoa0906085
  26. Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res 2007;67:3970-3975  https://doi.org/10.1158/0008-5472.CAN-06-3822
  27. Lee HJ, Goo JM, Lee CH, Park CM, Kim KG, Park EA, et al. Predictive CT findings of malignancy in ground-glass nodules on thin-section chest CT: the effects on radiologist performance. Eur Radiol 2009;19:552-560  https://doi.org/10.1007/s00330-008-1188-2
  28. Nakazono T, Sakao Y, Yamaguchi K, Imai S, Kumazoe H, Kudo S. Subtypes of peripheral adenocarcinoma of the lung: differentiation by thin-section CT. Eur Radiol 2005;15:1563-1568  https://doi.org/10.1007/s00330-004-2595-7
  29. Zwirewich CV, Vedal S, Miller RR, Muller NL. Solitary pulmonary nodule: high-resolution CT and radiologic-pathologic correlation. Radiology 1991;179:469-476  https://doi.org/10.1148/radiology.179.2.2014294
  30. Sica G, Yoshizawa A, Sima CS, Azzoli CG, Downey RJ, Rusch VW, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010;34:1155-1162  https://doi.org/10.1097/PAS.0b013e3181e4ee32
  31. Suh YJ, Lee HJ, Kim YT, Kang CH, Park IK, Jeon YK, et al. Added prognostic value of CT characteristics and IASLC/ATS/ERS histologic subtype in surgically resected lung adenocarcinomas. Lung Cancer 2018;120:130-136  https://doi.org/10.1016/j.lungcan.2018.04.007
  32. Gao S, Stein S, Petre EN, Shady W, Durack JC, Ridge C, et al. Micropapillary and/or solid histologic subtype based on pre-treatment biopsy predicts local recurrence after thermal ablation of lung adenocarcinoma. Cardiovasc Intervent Radiol 2018;41:253-259  https://doi.org/10.1007/s00270-017-1760-8
  33. Leeman JE, Rimner A, Montecalvo J, Hsu M, Zhang Z, von Reibnitz D, et al. Histologic subtype in core lung biopsies of early-stage lung adenocarcinoma is a prognostic factor for treatment response and failure patterns after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2017;97:138-145  https://doi.org/10.1016/j.ijrobp.2016.09.037
  34. Nitadori J, Bograd AJ, Kadota K, Sima CS, Rizk NP, Morales EA, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst 2013;105:1212-1220  https://doi.org/10.1093/jnci/djt166
  35. Huang KY, Ko PZ, Yao CW, Hsu CN, Fang HY, Tu CY, et al. Inaccuracy of lung adenocarcinoma subtyping using preoperative biopsy specimens. J Thorac Cardiovasc Surg 2017;154:332-339.e331  https://doi.org/10.1016/j.jtcvs.2017.02.059
  36. American College of Radiology. Lung CT screening reporting and data system (Lung-RADS). Acr.org Web site. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads. Accessed January 8, 2020 
  37. Han D, Heuvelmans MA, Oudkerk M. Volume versus diameter assessment of small pulmonary nodules in CT lung cancer screening. Transl Lung Cancer Res 2017;6:52-61  https://doi.org/10.21037/tlcr.2017.01.05
  38. Kim H, Park CM. Current perspectives for the size measurement of screening-detected lung nodules. J Thorac Dis 2018;10:1242-1244 https://doi.org/10.21037/jtd.2018.03.24